Learning Objectives After completing this course, the reader will be able to: Discuss the
currently available SCLC treatment options. Describe the benefits of integrating thoracic …

In the US, the prevalence of small cell lung cancer (SCLC) is declining, probably reflecting
the decreasing prevalence of tobacco use. However, a significant number of patients will …

PURPOSE: VERO is a novel platform for image guided stereotactic body radiotherapy.
Orthogonal gimbals hold the linac-MLC assembly allowing real-time moving tumor tracking …

Tumor tracking using a dynamic multileaf collimator (DMLC) represents a promising
approach for intrafraction motion management in thoracic and abdominal cancer …

Qualitätsindikatoren wurden durch Sens et al. wie folgt definiert:„Ein Indikator ist ein
quantitatives Maß, welches zum Monitoring und zur Bewertung der Qualität wichtiger …

The most common cause of cancer-related deaths in Europe in 2006 is lung cancer
(estimated 334 800 deaths). After prostate cancer, lung cancer is the most frequent type of …

Approximately 15% of lung cancer cases are of the small cell subtype, but this variant is
highly aggressive and is often diagnosed at advanced stages. Outcomes after current …

Small-cell lung carcinomas (SCLC) represent 15-18% of all lung cancers. As SCLC has a
high propensity for early metastatic dissemination, less than a third of patients have limited …

Limited-stage (LS) small-cell lung cancer (SCLC) remains a therapeutic challenge to
medical and radiation oncologists. The treatment of LS-SCLC has evolved significantly over …

Overview Worldwide, lung cancer is responsible for the largest number of cancer‐related
deaths, and reducing tobacco consumption is the most effective way to reduce lung cancer …